期刊
CELL
卷 162, 期 6, 页码 1257-1270出版社
CELL PRESS
DOI: 10.1016/j.cell.2015.08.015
关键词
-
资金
- Cancer Research UK
- Francis Crick Institute
- European Research Council Advanced Researcher Grant
- EMBO Long-Term Fellowship
- Rubicon Fellowship from the Netherlands Organization for Scientific Research
- Cancer Research UK [19279, 15689, 12100, 17240] Funding Source: researchfish
- The Francis Crick Institute [10002, 10136, 10138, 10334, 10144] Funding Source: researchfish
The mechanisms by which melanoma and other cancer cells evade anti-tumor immunity remain incompletely understood. Here, we show that the growth of tumors formed by mutant Braf(V600E) mouse melanoma cells in an immunocompetent host requires their production of prostaglandin E2, which suppresses immunity and fuels tumor-promoting inflammation. Genetic ablation of cyclooxygenases (COX) or prostaglandin E synthases in Braf(V600E) mouse melanoma cells, as well as in Nras(G12D) melanoma or in breast or colorectal cancer cells, renders them susceptible to immune control and provokes a shift in the tumor inflammatory profile toward classic anti-cancer immune pathways. This mouse COX-dependent inflammatory signature is remarkably conserved in human cutaneous melanoma biopsies, arguing for COX activity as a driver of immune suppression across species. Pre-clinical data demonstrate that inhibition of COX synergizes with anti-PD-1 blockade in inducing eradication of tumors, implying that COX inhibitors could be useful adjuvants for immune-based therapies in cancer patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据